Evidence map›Paper›PMID 36407948›Full record

ArticleACS pharmacology & translational science2022

Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice.

Grant C Glatfelter, Eline Pottie, John S Partilla, Alexander M Sherwood, Kristi Kaylo, Duyen N K Pham, Marilyn Naeem, Vamshikrishna Reddy Sammeta, Stacie DeBoer, James A Golen and 5 more

Open access · greenAbstract read
In one paragraph

Article in ACS pharmacology & translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 85 citations in OpenAlex.

  1. Crystal structures of new psychoactive substances 4-HO-DET and 4-AcO-DET.Acta crystallographica. Section E, Crystallographic communications · 2026
    Article
  2. Review
  3. Syntheses and structures of two norpsilocin derivatives:Acta crystallographica. Section E, Crystallographic communications · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Grant C GlatfelterDesigner Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland 21224, United States.ORCID https://orcid.org/0000-0003-1011-9083
Eline PottieLaboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Campus Heymans, Ottergemsesteenweg 460, 9000 Ghent, Belgium.
John S PartillaDesigner Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland 21224, United States.
Alexander M SherwoodUsona Institute, Madison, Wisconsin 53711, United States.ORCID https://orcid.org/0000-0003-0895-0791
Kristi KayloUsona Institute, Madison, Wisconsin 53711, United States.
Duyen N K PhamDepartment of Chemistry & Biochemistry, University of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States.
Marilyn NaeemDepartment of Chemistry & Biochemistry, University of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States.
Vamshikrishna Reddy SammetaDepartment of Chemistry & Biochemistry, University of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States.
Stacie DeBoerDepartment of Chemistry, University of Wyoming, Laramie, Wyoming 82071, United States.
James A GolenDepartment of Chemistry & Biochemistry, University of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States.
Elliott B HulleyDepartment of Chemistry, University of Wyoming, Laramie, Wyoming 82071, United States.ORCID https://orcid.org/0000-0002-2630-3689
Christophe P StoveLaboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Campus Heymans, Ottergemsesteenweg 460, 9000 Ghent, Belgium.ORCID https://orcid.org/0000-0001-7126-348X
Andrew R ChadeayneCaaMTech, Inc., Issaquah, Washington 98027, United States.
David R MankeDepartment of Chemistry & Biochemistry, University of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States.ORCID https://orcid.org/0000-0002-2513-4801
Michael H BaumannDesigner Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland 21224, United States.ORCID https://orcid.org/0000-0001-7758-1470
University of Massachusetts Dartmouth · USNational Institute on Drug Abuse · USGhent University · BEUniversity of Wyoming · USUsona Institute · US

Funding

Development of Dual Dopamine/Serotonin Releasing AgentsZ01DA000522 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI ROTHMAN, RICHARD · 2008 to 2008
$598k
Intramural NIH HHS Z01 DA000522
6 · The paper itself

Abstract

4-Phosphoryloxy-

Identifiers

PMID36407948
PMCPMC9667540
OpenAlexW4308486832

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.